Form 4: Director Martine Zimmermann Receives LGND Equity Grant

Ligand Pharmaceuticals director Martine Zimmermann was granted restricted stock units and stock options following the company's annual meeting.

Summary

• Director Martine Zimmermann acquired 836 restricted stock units (RSUs) on June 5, 2026.
• The company withheld 182 shares to cover tax liabilities associated with the RSU settlement.
• Zimmermann was granted 2,938 non-qualified stock options with an exercise price of $237.
• The total beneficial ownership for Zimmermann following these transactions is 5,097 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company performance.

Positives

• Equity-based compensation aligns director interests with long-term shareholder value.
• The grants reflect standard corporate governance practices following an annual meeting.

Negatives

• The issuance of new equity and options results in minor dilution for existing shareholders.

Risks

• Future share price volatility could impact the value of the granted options.
• Vesting conditions are subject to the timing of the next annual meeting or the first anniversary of the grant.

Future Outlook

The granted RSUs and options are set to vest on the earlier of the next annual meeting or the first anniversary of the grant date (June 5, 2027).

Management Comments

• The grants were approved by the Board of Directors at the annual meeting held on June 5, 2026.

Industry Context

StockSavvy.ai notes that equity grants to directors following annual meetings are standard practice in the biotechnology sector to ensure board alignment with corporate performance and shareholder interests.

Comparison to Industry Standards

• The use of RSUs and stock options as director compensation is consistent with standard practices for mid-cap pharmaceutical companies.
• The vesting schedule of one year is typical for director equity awards in the industry.

Corporate Governance

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of the granted RSUs and options on or before June 5, 2027.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Form 4, Insider Trading, Equity Compensation, Director Compensation